​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics (AXSM) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $220.27, with a high of $260.00 and a low of $193.00. This represents a 19.37% increase from the last price of $184.52.

$50 $100 $150 $200 $250 $300 High: $260 Avg: $220.27 Low: $193 Last Closed Price: $184.52

AXSM Stock Rating

Axsome Therapeutics stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (96.00%), 1 Hold (4.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 24 Strong Sell Sell Hold Buy Strong Buy

AXSM Price Target Upside V Benchmarks

TypeNameUpside
StockAxsome Therapeutics19.37%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts121624
Avg Price Target$218.58$209.94$196.38
Last Closing Price$184.52$184.52$184.52
Upside/Downside18.46%13.78%6.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26416---20
Dec, 25416---20
Nov, 25515---20
Oct, 25515---20
Sep, 25514---19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 21, 2026Leonid TimashevRBC Capital$219.00$184.5018.70%18.69%
Jan 20, 2026H.C. Wainwright$260.00$177.2746.67%40.91%
Jan 16, 2026Piper Sandler$223.00$174.1428.06%20.85%
Jan 13, 2026Robert W. Baird$209.00$175.9918.76%13.27%
Jan 13, 2026Wells Fargo$193.00$176.829.15%4.60%
Jan 08, 2026Morgan Stanley$204.00$170.6919.51%10.56%
Jan 06, 2026UBS$248.00$175.1541.59%34.40%
Jan 05, 2026Ami FadiaNeedham$225.00$178.6925.92%21.94%
Jan 05, 2026Raghuram SelvarajuH.C. Wainwright$200.00$178.6911.93%8.39%
Jan 02, 2026Yatin SunejaGuggenheim$205.00$179.1414.44%11.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 16, 2026Piper SandlerOverweightOverweighthold
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold
Jan 13, 2026Wells FargoOverweightOverweighthold
Jan 08, 2026Morgan StanleyOverweightReducedowngrade
Jan 06, 2026UBSBuyBuyhold
Jan 05, 2026NeedhamBuyBuyhold
Jan 05, 2026H.C. WainwrightBuyBuyhold
Jan 02, 2026GuggenheimBuyBuyhold
Dec 31, 2025OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-4 $2 $8 $14 $20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$-5.27$-5.99----
Avg Forecast$-4.33$-4.26$-5.46$-1.86$3.49$8.94$14.40
High Forecast$-3.58$-4.09$-4.84$1.33$7.55$15.48$18.28
Low Forecast$-5.22$-4.59$-6.42$-6.84$-1.77$1.68$11.37
Surprise %12.24%23.71%9.71%----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.04M$270.60M$385.69M----
Avg Forecast$46.98M$268.30M$384.09M$632.39M$1.02B$1.47B$2.00B
High Forecast$54.34M$269.66M$387.81M$761.98M$1.03B$1.47B$2.41B
Low Forecast$40.70M$265.55M$380.46M$529.02M$1.02B$1.47B$1.67B
Surprise %6.51%0.86%0.42%----

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-197.77M$-239.24M$-287.22M----
Avg Forecast$-196.81M$-197.28M$-255.63M$-117.53M$130.33M$454.59M$654.27M
High Forecast$-162.61M$-186.00M$-219.63M$60.27M$342.78M$703.18M$830.30M
Low Forecast$-236.92M$-208.57M$-291.63M$-310.79M$-80.59M$76.31M$516.45M
Surprise %0.49%21.27%12.36%----

AXSM Forecast FAQ

Is Axsome Therapeutics stock a buy?

Axsome Therapeutics stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Axsome Therapeutics is a favorable investment for most analysts.

What is Axsome Therapeutics's price target?

Axsome Therapeutics's price target, set by 25 Wall Street analysts, averages $220.27 over the next 12 months. The price target range spans from $193 at the low end to $260 at the high end, suggesting a potential 19.37% change from the previous closing price of $184.52.

How does Axsome Therapeutics stock forecast compare to its benchmarks?

Axsome Therapeutics's stock forecast shows a 19.37% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Axsome Therapeutics over the past three months?

  • January 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Axsome Therapeutics’s EPS forecast?

Axsome Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.86, marking a -68.95% decrease from the reported $-5.99 in 2024. Estimates for the following years are $3.49 in 2026, $8.94 in 2027, and $14.4 in 2028.

What is Axsome Therapeutics’s revenue forecast?

Axsome Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $632.39M, reflecting a 63.96% increase from the reported $385.69M in 2024. The forecast for 2026 is $1.02B, followed by $1.47B for 2027, and $2B for 2028.

What is Axsome Therapeutics’s net income forecast?

Axsome Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-118M, representing a -59.08% decrease from the reported $-287M in 2024. Projections indicate $130.33M in 2026, $454.59M in 2027, and $654.27M in 2028.